Reported results
- Revenue for the third quarter of 2026 was $221.6 million, a 14.9% increase compared to $192.9 million in the third quarter of 2025.
- Gross margin was 74.2%, a 310-basis point increase compared to the third quarter of 2025.
- GAAP net loss for the third quarter of 2026 was $29.9 million, or GAAP net loss per diluted share of $0.90, compared to GAAP net loss of $5.2 million, or GAAP net loss per diluted share of $0.16, in the third quarter of 2025.
- Adjusted EBITDA was $51.2 million and adjusted EBITDA margin was 23.1% for the third quarter of 2026.
- Adjusted net income for the third quarter of 2026 was $27.8 million, or adjusted net income per diluted share of $0.82, compared to adjusted net loss of $2.0 million, or adjusted net loss per diluted share of $0.06, in the third quarter of 2025.
Guidance
- For full year 2026, revenue is expected to be between $890 million and $895 million, including approximately $16 million of expected VitalConnect revenue contribution.
- For full year 2026, adjusted EBITDA margin is expected to be between 15.5% and 16.0%.
Price and volatility reaction
The stock moved -30.7% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved +0.2 vol points across the event (constant-maturity series — not the front-week crush).
| Measure | Value | Basis |
|---|---|---|
| Close before release | 130.19 | 2026-11-05 |
| Close after release | 90.22 | 2026-11-06 |
| Realised move | -30.7% | close to close |
| 30d ATM IV change | +0.2 vol pts | constant-maturity series, not the front expiry |
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-05 (8-K, Item 2.02). Read the original filing on sec.gov.
